Search

Your search keyword '"Pérol, M."' showing total 11 results

Search Constraints

Start Over You searched for: Author "Pérol, M." Remove constraint Author: "Pérol, M." Topic antineoplastic agents Remove constraint Topic: antineoplastic agents
11 results on '"Pérol, M."'

Search Results

1. Nivolumab-Induced Acute Diabetes Mellitus and Hypophysitis in a Patient with Advanced Pulmonary Pleomorphic Carcinoma with a Prolonged Tumor Response.

2. Alectinib for treatment of ALK-positive non-small-cell lung cancer.

3. Bevacizumab in Patients with Nonsquamous Non-Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study.

4. Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study.

5. Reply to N. Singh et al.

6. Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer.

7. [Maintenance therapy in advanced non-small cell lung cancer: A new paradigm?].

8. [From ASCO and WCLC 2005 to the clinical practice: targeted therapies].

9. cN-II expression predicts survival in patients receiving gemcitabine for advanced non-small cell lung cancer.

10. Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy.

11. Docetaxel and concurrent radiotherapy after two cycles of induction chemotherapy with cisplatin and vinorelbine in patients with locally advanced non-small-cell lung cancer: A phase II trial conducted by the Groupe Français de Pneumo-Cancérologie (GFPC)

Catalog

Books, media, physical & digital resources